Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

APTX - Aptinyx Inc.

Previous close
0.08
0.080   100.000%

Share volume: 0
Last Updated: Thu 18 May 2023 08:01:30 PM CEST
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 50%
Dept financing 3%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
3.11%
2 Year
-71.63%
Key data
Stock price
$0.08
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.10 - $0.10
52 WEEK CHANGE
$3.11
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
67.716 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Andrew Kidd
Region: US
Website: www.aptinyx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Aptinyx Inc. focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company has a research collaboration agreement with Allergan plc.

Recent news